2mg Bortezomib Injection IP

2mg Bortezomib Injection IP Specification

Indication
For treatment of Multiple Myeloma and Mantle Cell Lymphoma

Salt Composition
Bortezomib 2 mg

Brand Name
Bortezomib Injection IP

Life Span
24 months from manufacturing

Origin of Medicine
India

Pacakaging (Quantity Per Box)
Single vial per box

Packaging Type
Vial with external carton

Dosage Form
Lyophilized Powder for Injection

Drug Type
Prescription Only, Injectable, Allopathic

Ingredients
Bortezomib

Physical Form
Injection, Injection

Function
Anticancer / Antineoplastic Agent, Anti-cancer (Proteasome inhibitor)

Recommended For
Multiple Myeloma, Mantle Cell Lymphoma

Dosage
2 mg per vial (to be administered as per physicians direction)

Dosage Guidelines
As directed by oncologist or physician

Suitable For
Adults, Adults

Quantity
1 Vial

Storage Instructions
Store below 25C, protect from light and moisture

Prescription Status
Requires prescription

Shelf Life
2 years from date of manufacture

Route of Administration
Intravenous (IV) or Subcutaneous (SC)

Strength
2 mg per vial

Therapeutic Class
Antineoplastic agent

Marketed By
As per label

Reconstitution
To be reconstituted with sterile water for injection

Appearance
Lyophilized white to off-white powder

2mg Bortezomib Injection IP Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash Against Delivery (CAD), Cash on Delivery (COD), Cash in Advance (CID)

Supply Ability
100 Boxes Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

About 2mg Bortezomib Injection IP

Experience instant checkout and secure your reserve of the meritorious 2mg Bortezomib Injection IP, a kingly choice in oncological therapy. Lustrous for its efficacy, this antineoplastic agent is specially formulated for intravenous (IV) or subcutaneous (SC) administration after reconstitution with sterile water. Appearing as a lyophilized white to off-white powder, each vial contains 2 mg of Bortezomib. Designed for adults battling Multiple Myeloma or Mantle Cell Lymphoma, it is strictly dispensed on prescription. Explore trusted, high-quality care made in India, with a shelf life of 24 months.

Key Features and Competitive Advantages

2mg Bortezomib Injection IP boasts a precise lyophilized powder form, suitable for both IV and SC administration, ensuring flexibility in treatment. Reserved primarily for adults confronting Multiple Myeloma and Mantle Cell Lymphoma, its competitive advantages include long shelf life, practitioner-specific dosage, and robust packaging. The formulation is an effective antineoplastic agent, expertly engineered for potency and safety under the guidance of medical professionals, making it a preferred choice for oncologists and hospitals alike.

Supply Ability, Delivery Time & Export Excellence

Estimates for 2mg Bortezomib Injection IP supply reflect a reliable volume suited for both domestic and global demand. Efficient transportation and prompt freight services guarantee timely delivery, ensuring product viability throughout its shelf life. Main export markets include Asia, Africa, and the Middle East, where demand is consistently met. Our distribution channels are optimized to streamline orders from procurement to dispatch, promising seamless, on-time supply and professional handling at every logistical phase.

FAQ's of 2mg Bortezomib Injection IP:

Q: How should 2mg Bortezomib Injection IP be administered?

A: 2mg Bortezomib Injection IP can be administered intravenously (IV) or subcutaneously (SC), and should be given strictly as directed by your oncologist or physician.

Q: What are the main indications for using Bortezomib Injection IP?

A: This injection is primarily recommended for adults in the treatment of Multiple Myeloma and Mantle Cell Lymphoma, based on a medical professional's prescription.

Q: When is the product considered suitable for administration?

A: 2mg Bortezomib Injection IP is suitable for adults diagnosed with Multiple Myeloma or Mantle Cell Lymphoma, and only under close medical supervision.

Q: Where should the injection vial be stored before use?

A: Store the vial below 25C, protected from light and moisture, to maintain its stability and efficacy before reconstitution and administration.

Q: What is the process for preparing Bortezomib Injection IP for use?

A: The lyophilized powder must be reconstituted with sterile water for injection by a healthcare professional prior to administration for safe and effective use.

Q: How does Bortezomib Injection IP benefit patients?

A: Bortezomib Injection IP works as a proteasome inhibitor, providing significant therapeutic benefits for patients by targeting and inhibiting cancer cell growth and proliferation.